18 October 2021
The Health Policy Partnership (HPP) is hosting the session ‘Radioligand therapy: multidisciplinary collaboration for health system readiness’ at the European Multidisciplinary Congress on Urological Cancers (EMUC21) in Athens, Greece, on 25 November. We welcome all EMUC21 attendees to join us.
In light of emerging clinical trial data, the session will focus on the possible role of radioligand therapy in prostate cancer care. With potential regulatory approval for radioligand therapy in prostate cancer on the horizon, we must carefully plan how the approach can be integrated into existing care pathways.
Professor Hein Van Poppel (European Association of Urology) will lead a presentation on the importance of a multidisciplinary approach to prostate cancer care. Dr John Buscombe (British Nuclear Medicine Society) will follow with a session on what radioligand therapy is. Erik Briers (European Cancer Patient Coalition) will then analyse the potential impact of radioligand therapy from a patient perspective.
Christine Ridout (HPP) will go on to discuss how the recently launched Radioligand Therapy Readiness Assessment Framework can be used to support proactive and data-driven policy development for radioligand therapy, presenting key findings and policy priorities from the UK and US. Ms Ridout will also moderate a panel discussion with Dr Andreas Charalambous (European Oncology Nursing Society), Dr Jolanta Kunikowska (European Association of Nuclear Medicine), Professor Boris Hadaschik (Essen University Hospital), Professor Silke Gillessen (Oncology Institute of Southern Switzerland) and Professor Gert De Meerleer (UZ Leuven) to discuss how the clinical community can create a ready and multidisciplinary system for radioligand therapy.
We hope that this session will catalyse discussions on what a ready policy environment for radioligand therapy looks like at both the EU and national levels. We look forward to seeing you there!
For more information and to register for EMUC21, please visit www.emuc21.org.